Analysis of IL-17 protein levels along cancer stages B1-D in patients showed that they were significantly higher in comparison to the a) corresponding levels of K-ras negative patients (62% vs. 38%), and b) healthy controls (62% vs. 16%) (Figure 2A). The gene discussed is IL17A; the disease is cancer.